Kineta gets investment for autoimmune disease drug candidate

06/7/2010 | Seattle Times, The

Kineta has received an undisclosed investment sum from the Iacocca Family Foundation to advance the development of ShK-186, its drug candidate for autoimmune diseases such as Type 1 diabetes and multiple sclerosis. The Seattle-based biotech firm plans to conduct a Phase I trial of the drug, which inhibits some of the white blood cells that activate inflammation in autoimmune conditions, later this year.

View Full Article in:

Seattle Times, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX